Celularity Inc.
CELU
Positions held
Your positionsCELU isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $47.38M | Enterprise value | $115.09M | Trailing P/E | — | Forward P/E | -2.56 |
| PEG | — | Price / book | -1.21 | Beta | 0.78 | Dividend yield | 0.00% |
| Revenue growth | -66.3% | Earnings growth | — | Gross margin | 5.3% | Operating margin | -2.6% |
| Profit margin | 0.0% | ROE | — | ROA | -32.3% | Debt / equity | — |
| Current ratio | 0.09 | Free cash flow | -$1.36M | Analyst recommendation | none | Mean target | — |
| 52w high | $2.55 | 52w low | $0.56 |
Quarterly
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $4.1M | $5.3M | $5.7M | $11.4M |
| Op margin | -537.5% | -244.1% | -276.6% | -91.8% |
| Net income | -$24.4M | -$23.1M | -$24.5M | -$19.8M |
| Gross margin | -79.7% | 26.1% | 8.6% | 68.9% |
| Gross profit | -$3.3M | $1.4M | $0.5M | $7.9M |
| Operating income | -$22.1M | -$12.9M | -$15.9M | -$10.5M |
- Revenue -22% vs prior quarter ($4.1M vs $5.3M).
- Gross margin -79.7% (was 26.1% prior quarter).
- Operating margin compressed to -537.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | — |
| Op margin | -230.9% | -71.1% | -335.9% | -824.9% | — |
| Net income | -$91.7M | -$57.9M | -$196M | $14.2M | — |
| Gross margin | 24.4% | 72.4% | 29.7% | -9.4% | — |
| Gross profit | $6.5M | $39.2M | $6.8M | -$1.7M | — |
| Operating income | -$61.3M | -$38.6M | -$76.5M | -$148M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
2026-09-29 · Celularity Announces Naveen Jain to Join Board of Directors
2026-08-27 · BC-Most Active Stocks
2026-08-27 · Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity
2026-08-27 · Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
2026-08-25 · Celularity Provides Update Regarding Nasdaq Listing Compliance
2026-08-20 · NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
2026-08-20 · NexGel Files to Register 15.25 Million Shares From Note Conversions
2026-08-17 · NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp
2026-08-17 · NEXGEL Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns